Egwuagu, Charles E
- National Eye Institute (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #2,993
- Sustained Excellence
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2007 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$2.3M
Full award amounts, FY2023
Award Records
5
Records listing this PI
Award-Linked Rank
#2,993
By linked amount among FY2023 PIs
Earliest Year Loaded
2007
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Egwuagu, Charles E as a PI. Multi-PI records show the full award amount for context.
- 1ZIAEY000350-24ZIAContact PIDevelopment of Immunologic therapies against uveitis$673.6Kaward amount
- 1ZIAEY000372-23ZIAContact PIMechanisms of immune homeostasis and regulation of intraocular inflammation$662.1Kaward amount
- $538.9Kaward amount
- 1ZIAEY000262-28ZIAContact PIRole of IL-12 family cytokines in human autoimmune Uveitis$250.2Kaward amount
- 1ZIAEY000280-32ZIAContact PISuppressors of Cytokine Signalling (SOCS) have Neuroprotective Roles in Retina$154Kaward amount
Award organization
Organizations that administered FY2023 awards listing Egwuagu, Charles E as a PI.
FY2023 award administered by National Eye Institute ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2007First NIH AwardNational Eye Institute
- 2007$500K Cumulative Funding
- 2007$1M Cumulative Funding
- 2007$2M Cumulative Funding
- 2007Entered Top 50% NationallyRanked #1730
- 2007Entered Top 25% NationallyRanked #1730
- 2007Entered Top 10% NationallyRanked #1730
- 2009$5M Cumulative Funding
- 2013$10M Cumulative Funding
- 2023$25M Cumulative Funding